Who are Dextromethorphan HBr's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): S (+) Ketamine, Magnesium sulfate 24 hours, Rémifentamil + KETAMINE, Naloxone + Ketamine, Ketamine plus usual care, Saline + Ketamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dextromethorphan-hbr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Dextromethorphan HBr — Competitive Intelligence Brief

Dextromethorphan HBr (Dextromethorphan HBr) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist; sigma-1 receptor agonist. Area: Supportive Care; Respiratory.

marketed NMDA receptor antagonist; sigma-1 receptor agonist NMDA receptor; sigma-1 receptor Supportive Care; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Dextromethorphan HBr (Dextromethorphan HBr) — Galera Therapeutics, Inc.. Dextromethorphan HBr is a sigma-1 receptor agonist and NMDA receptor antagonist that reduces cough by suppressing the cough reflex center in the medulla.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dextromethorphan HBr TARGET	Dextromethorphan HBr	Galera Therapeutics, Inc.	marketed	NMDA receptor antagonist; sigma-1 receptor agonist	NMDA receptor; sigma-1 receptor
S (+) Ketamine	S (+) Ketamine	Asker & Baerum Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Magnesium sulfate 24 hours	Magnesium sulfate 24 hours	Instituto Materno Infantil Prof. Fernando Figueira	marketed	NMDA receptor antagonist; tocolytic agent; anticonvulsant	NMDA receptor; L-type calcium channels
Rémifentamil + KETAMINE	Rémifentamil + KETAMINE	University Hospital, Clermont-Ferrand	marketed	Opioid + NMDA receptor antagonist combination	Mu-opioid receptor (remifentanil); NMDA receptor (ketamine)
Naloxone + Ketamine	Naloxone + Ketamine	Ullevaal University Hospital	marketed	Opioid antagonist + NMDA receptor antagonist combination	Opioid receptors (mu, delta, kappa) and NMDA receptor
Ketamine plus usual care	Ketamine plus usual care	The University of Texas Health Science Center, Houston	marketed	NMDA receptor antagonist	NMDA receptor
Saline + Ketamine	Saline + Ketamine	Ullevaal University Hospital	marketed	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor (glutamate-gated ion channel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist; sigma-1 receptor agonist class)

Galera Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dextromethorphan HBr — Competitive Intelligence Brief. https://druglandscape.com/ci/dextromethorphan-hbr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab